文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-Pentixafor PET/CT对非肿瘤患者肾上腺皮质肿物的功能评估

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor.
PubMed 文献 · J Nucl Med · 2021-07-22

功能侧化诊断敏感度97.8%、特异度87.5%;功能性腺瘤SUVmax 16.3±7.9高于无功能腺瘤4.4±1.7和增生5.5±2.7(P<0.0001)。

要点

  • 68Ga-pentixafor PET可无创功能侧化肾上腺皮质病变,敏感度97.8%。
  • 活性肾上腺皮质腺瘤SUVmax、LLR、LCR均显著高于无功能腺瘤和增生。
  • 较高摄取与肾上腺切除后良好结局相关。

核心结论

  • 68Ga-pentixafor PET/CT对肾上腺皮质肿物无创功能侧化和表征具良好潜力。

研究设计与样本

  • 81个肾上腺肿瘤亚型经组织学或随访确定,包括14个无功能结节、4个皮质醇分泌腺瘤、41个醛固酮分泌腺瘤、5例疑似单侧肾上腺增生、15例特发性醛固酮增生和2例嗜铬细胞瘤。
  • 通过视觉分析计算功能侧化诊断效能,并计算SUVmax、病灶SUVmax/正常肝SUVmean比值(LLR)和病灶SUVmax/对侧肾上腺组织SUVmean比值(LCR),对15例行动态分析。

主要发现

  • 68Ga-pentixafor PET对肾上腺皮质病变功能侧化的敏感度为97.8%(45/46),特异度为87.5%(14/16)。
  • 2例嗜铬细胞瘤病灶pentixafor摄取低于正常肾上腺。
  • 功能性(活跃)肾上腺皮质腺瘤SUVmax为16.3±7.9,高于无功能(不活跃)腺瘤的4.4±1.7和增生病变的5.5±2.7(P<0.0001)。
  • 识别活跃肾上腺皮质腺瘤:SUVmax截断值7.1,敏感度90.9%、特异度85.3%(AUC 0.96;P<0.0001);LLR截断值2.5,敏感度95.5%、特异度88.2%(AUC 0.97;P<0.0001);LCR截断值2.4,敏感度88.6%、特异度91.8%(AUC 0.95;P<0.0001)。
  • 活跃肾上腺皮质腺瘤的图形流入速率常数显著高于不活跃腺瘤。

关键数值与推荐

  • 功能侧化诊断以视觉分析计算,敏感度97.8%(45/46)、特异度87.5%(14/16)。
  • 识别活跃肾上腺皮质腺瘤:SUVmax截断值7.1(敏感度90.9%、特异度85.3%,AUC 0.96)。
  • 识别活跃肾上腺皮质腺瘤:LLR截断值2.5(敏感度95.5%、特异度88.2%,AUC 0.97)。
  • 识别活跃肾上腺皮质腺瘤:LCR截断值2.4(敏感度88.6%、特异度91.8%,AUC 0.95)。

临床怎么用

  • 对CT发现的良性肾上腺肿物,68Ga-pentixafor PET/CT可用于无创功能侧化,辅助鉴别活跃肾上腺皮质腺瘤。
  • SUVmax≥7.1、LLR≥2.5或LCR≥2.4提示活跃肾上腺皮质腺瘤可能,需结合临床。
  • 较高68Ga-pentixafor摄取与肾上腺切除后良好结局相关,或有助于预后评估。

局限性

  • 嗜铬细胞瘤仅2例,动态分析仅15例。
  • 单中心研究,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to investigate the diagnostic and prognostic value of 68Ga-pentixafor PET/CT imaging in noncancer patients with suspected adrenal masses. Methods: Sixty-four patients who had benign adrenal masses on CT were retrospectively included in our study. All patients underwent 68Ga-pentixafor PET/CT, and 56 of these patients subsequently underwent adrenalectomy. The subtypes of 81 adrenal tumors, including 14 nonfunctioning adrenal nodules, 4 cortisol-producing adenomas, 41 aldosterone-producing adenomas, 5 cases of suspected unilateral adrenal hyperplasia, 15 cases of idiopathic aldosterone hyperplasia, and 2 pheochromocytomas, were determined by histology or follow-up evaluations. The diagnostic efficiency of functional lateralization was calculated by visual analysis. Semiquantitative parameters of these lesions, including SUVmax, the ratio of lesional SUVmax to normal liver SUVmean (LLR), and the ratio of lesional SUVmax to contralateral adrenal tissue SUVmean (LCR), were also calculated. Dynamic analysis was also performed on 15 patients. In addition, clinical outcomes were assessed and compared in patients who underwent adrenalectomy. Results: The sensitivity and specificity of 68Ga-pentixafor PET for functional lateralization in patients with adrenocortical lesions were 97.8% (45/46) and 87.5% (14/16), respectively. The 2 pheochromocytoma lesions had lower pentixafor uptake than the normal adrenal glands. Functioning (active) adrenocortical adenomas showed an elevated SUVmax of 16.3 ± 7.9, in comparison to 4.4 ± 1.7 in nonfunctioning (inactive) adenomas and 5.5 ± 2.7 in hyperplasia lesions (P < 0.0001). To identify active adrenocortical adenomas, a cutoff of 7.1 for SUVmax showed a sensitivity of 90.9% and a specificity of 85.3% (area under receiver-operating-characteristic curve, 0.96; P < 0.0001); a cutoff of 2.5 for LLR showed a sensitivity of 95.5% and a specificity of 88.2% (area under receiver-operating-characteristic curve, 0.97; P < 0.0001); and a cutoff of 2.4 for LCR showed a sensitivity of 88.6% and a specificity of 91.8% (area under receiver-operating-characteristic curve, 0.95; P < 0.0001). The graphical influx rate constant of active adrenocortical adenomas was significantly higher than that of inactive adenomas. Uptake values for 68Ga-pentixafor were significantly higher in patients with preferable outcomes (cured/improved) (SUVmax, 15.5 ± 8.0; LLR, 6.5 ± 4.3; LCR, 6.2 ± 5.0) than in patients with nonpreferable outcomes (no improvement) (SUVmax, 4.2 ± 0.5; LLR, 1.3 ± 0.2; LCR, 1.5 ± 0.6; all P < 0.0001). Conclusion:68Ga-pentixafor PET/CT imaging exhibits great potential for noninvasive functional lateralization and characterization in patients with adrenocortical masses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ding J, Tong A, Zhang Y, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor. J Nucl Med. 2021. PMID: 34301781. doi:10.2967/jnumed.121.261964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。